Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Opening Session Panel Discussion

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Advertisement

Advertisement




Aug
21
Today In Oncology
FDA Seeks Public Input Relating to Regulatory Considerations for Generative AI–Enabled Medical Devices
Pilots and Flight Attendants Show Elevated Radiation-Related Cancer Mortality
INTerpath-001 Trial of mRNA-Based Individualized Neoantigen Therapy Meets Primary and Key Secondary Endpoints in Patients With High-Risk Resected Melanoma
Chemotherapy, Immunotherapy, and Targeted Therapy in Advanced, Refractory Malignancies
Early Histotripsy Use for Liver Tumors Raises Questions About Patient Selection
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo